IntegraGen is pleased to announce that a comprehensive summary of the results of validation studies associated with the company’s proprietary miR-31-3p expression test has been published online in Biomarker Insights following peer-review.

The paper entitled “Technical validation of a reverse-transcription quantitative polymerase chain reaction in vitro diagnostic test for the determination of miR-31-3p expression levels in formalin-fixed paraffin-embedded (FFPE) metastatic colorectal cancer tumor specimens” reviews the analytical sensitivity and specificity, robustness, reproducibility, repeatability and accuracy of the test under a number of testing conditions using several differing testing platforms.

The data from these studies confirms the ability of the testing method to provide an analytically precise assay for the clinical measurement of miR-31-3p from FFPE tumor samples in patients with metastatic colorectal cancer.

Click here to view full publication.